BQPrime
•Business
Business & Economics
Natco Pharma Q2 Results Review - Ex-Revlimid Growth Healthy; Valuation Attractive: ICICI Securities
79% Informative
We raise our rating on the stoc 'Add' 'Add' and revise our target pric Rs 875 s 875.
Revenue growth of 139%/65% for Q2/H1 FY24 was mainly driven by exports.
Management has retained FY24 prof India ter tax estimate of Rs 10-12 billion.
Windfall is invested in research and development (8-10% of sales) to build generic pharma and agrochemical pipeline. ICICI Securities Report g Natco Pharma Ltd. n class="summaryFeed_highLightText__NxlGi">DISCLAIMER 139%/65% Light Q2 xt__NxlGi">Rs 875 'Add' < 56%/54% ass="summaryFeed_highLightText__NxlGi">Natco Rs 10-12 billion d_highLightText__ Rs 7.9 billion /span> gRevlimid ryFeed_highLightText__NxlGi">F483 8-10% class="summaryFeed_highLightText__NxlGi">The ~9% Q2 2-3%
VR Score
89
Informative language
92
Neutral language
89
Article tone
formal
Language
English
Language complexity
40
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links